Shanghai OPM Biosciences Co. Ltd.

Shanghai OPM Biosciences Co. has experienced a recent evaluation adjustment, influenced by various financial metrics and trends. The company reported a significant operating cash flow and net sales growth in the latest quarter, although it continues to face long-term challenges in profitability and sales growth rates.

Shanghai OPM Biosciences Co. saw a notable decline in its stock today, contrasting with the broader market's performance. Despite reporting strong half-year net sales growth, the company faces challenges, including a significant drop in net profit over the past year, amid a tough market environment.

Shanghai OPM Biosciences Co. saw a notable stock increase on March 6, 2026, reaching an intraday high. However, the company has faced challenges, with declines over the past week and month, while maintaining a modest yearly return. Its market capitalization is CNY 5,991 million, indicating mid-cap status.